

**BLAU FARMACÊUTICA S.A.**

Publicly Held Corporation

NIRE 35.300.416.406

CVM Code 2462-7

**NOTICE TO THE MARKET**

**Signing of Distribution Agreement with Medytox**

BLAU FARMACÊUTICA S.A. (Ticker: BLAU3; "Blau" or "Company"), publicly-held biotechnology company, hereby informs its shareholders and the market in general regarding the signing of a new commercial agreement for botulinum toxin, encompassing the total amount of USD 73,000,000.00 (seventy-three million dollars), with South Korean company Medytox Inc ("Commercial Agreement" and "Medytox", respectively). The Commercial Agreement grants the Company exclusive representation and distribution rights in Brazil of a product called 'Botulift' - botulinum toxin, manufactured by Medytox, with contractual possibilities of, in the future, expanding distribution towards other products and/or other Latin American countries.

The Commercial Agreement was signed in the context of the Company's acquisition of Laboratório Químico e Farmacêutico Bergamo Ltda. ("Bergamo"), which holds distribution rights of Medytox products in Brazil. With the acquisition of Bergamo and the signing of the Commercial Agreement, the Company, through its strategic committee, decided to concentrate its botulinum toxin business with Medytox, and will hire a specialized advisor in order to seek strategic alternatives, together with the Company's other partner supplier, for the botulinum toxin brand called 'Botulim'.

Blau also clarifies the market that sales of Botulim will continue through the Blau Aesthetics unit, as will Botulift, through Dermadream, throughout 2024.

Medytox is a research-based bio pharmaceutical company that developed a botulinum toxin product for the first time in South Korea (the fourth in the world), and engages in the development, manufacturing, marketing and sales of neurotoxin products as its main business. Since its establishment in 2000, Medytox has developed and evolved into a global R&D company with the launch of its main neurotoxin product.

Roberto Morais, the Company's Chief Strategy and M&A Officer, said, "*We are very happy with this partnership, Medytox has long experience in aesthetic products, including botulinum toxin, and strong R&D capabilities, with a solid pipeline, which can offer us new products in the future, to be distributed in the region, strengthening the Company's aesthetics business unit.*"

Cotia, March 25, 2024.

**Douglas Leandro Rodrigues**

CFO & IRO

**About Blau Farmacêutica:**

Blau is a leading pharmaceutical company in the institutional segment and a pioneer in biotechnology, with a portfolio of owned brands of highly complex drugs focused on relevant segments in the industry, such as immunology, hematology, oncology, nephrology, and infectious diseases, among others, acting in several therapeutical classes.

Blau is present across the continent, currently in seven countries in Latin America – Brazil, Argentina, Colombia, Chile, Equator, Peru, and Uruguay, and in the United States, with a modern pharmaceutical industrial complex composed of five facilities in Brazil, with state-of-the-art technology, dedicated to the production of biological, oncological medicines, antibiotics, injectable anesthetics, and biotechnology.